Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | COMT | P21964 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ASPH | Q12797 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5252542 | 0.86 | TSHR (0.51) | TSHRL3MBTL1TDP1COMTCES2 | |
| SCHEMBL5252545 | 0.86 | TSHR (0.51) | TSHRL3MBTL1TDP1COMTCES2 | |
| SCHEMBL18806713 | 0.82 | PDGFRB (0.45) | TSHRL3MBTL1POLBMAPTMAPK1 | |
| SCHEMBL14333137 | 0.79 | ALDH1A1 (0.47) | TSHRTDP1POLBMAPTMEN1 | |
| SCHEMBL7083217 | 0.77 | KDM4E (0.50) | TSHRL3MBTL1TDP1HCAR2MAPT | |
| SCHEMBL31481315 | 0.77 | GPR35 (0.47) | TSHRCES2CES1MAPTSMN1; SMN2 | |
| SCHEMBL1338068 | 0.76 | LMNA (0.47) | TSHRL3MBTL1TDP1COMTPOLB | |
| SCHEMBL3360541 | 0.76 | ALDH1A1 (0.46) | TSHRTDP1MAPTLMNARAB9A | |
| SCHEMBL14333101 | 0.76 | ALDH1A1 (0.50) | TSHRTDP1MAPTLMNASMN1; SMN2 | |
| SCHEMBL28635523 | 0.75 | KDM4E (0.48) | TSHRL3MBTL1TDP1HCAR2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096527-B2 | TRPM8 antagonists and their use in treatments | AMGEN INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140171406-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140171639-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-8710043-B2 | TRPM8 antagonists and their use in treatments | AMGEN INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-20130157996-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171639-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | TRPM8, TRPM7, TRPM5 | TSHR 2647/4885L3MBTL1 4729/4885TDP1 2636/4885 |
| US-20140171406-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | TRPM8, TRPM7, TRPM5 | TSHR 2647/4885L3MBTL1 4729/4885TDP1 2636/4885 |
| US-20130157996-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | TRPM8, TRPM7, TRPM5 | TSHR 2647/4885L3MBTL1 4729/4885TDP1 2636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.